Australia’s Sigma Blocked From Marketing Effexor Generic
This article was originally published in PharmAsia News
Executive SummarySigma Pharmaceuticals of Australia lost a case in federal court in its attempt to market a generic version of U.S.-based Wyeth's antidepressant Effexor (venlafaxine). The court issued an injunction against Sigma marketing the drug until the validity of Wyeth's patent for Effexor is determined later this year in another court. Sigma already had begun importing its generic copy, Evelexa, and had been contacting possible customers about a drug it expected to deliver as early as June 1. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.